… In conclusion, selective inhibition of nuclear export is a promising treatment strategy.
Selinexor has demonstrated a manageable safety profile and preliminary evidence of single-agent …

… Having demonstrated single agent activity of SINE compounds in multiple NHL xenograft
models, we sought to evaluate the efficacy and tolerability of the selinexor-DEX and selinexor-…

… research to date on XPO1 inhibitors such as selinexor and other selective inhibitors of nuclear
export (SINEs), which are used to treat some cases of non-Hodgkin lymphoma. In vitro, in …

… Selinexor is a selective inhibitor of nuclear export and is an active agent in various … B-cell
lymphoma as well as multiple myeloma. Following oral administration, selinexor exhibits linear …

… in nuclear export inhibition have been successfully translated to bedside medicine in multiple
myeloma (MM) and non-Hodgkin lymphoma (… in XPO1 and MDM2 inhibitors (selinexor and …

… known as Selective Inhibitors of Nuclear Export (SINE) … Selective Inhibitors of Nuclear
Export compounds are orally … and T-cell non-Hodgkin lymphoma (NHL) subtypes including …

… The selective inhibitor of nuclear export, Selinexor, is one of the most scientifically … trial
in patients with relapsed or refractory non-Hodgkin’s lymphoma found that Selinexor was well …

… Selinexor (KPT-330) is a selective inhibitor of nuclear export (SINE) developed … nuclear
export, leading to increased nuclear retention of major tumor suppressor proteins and selective …

… agents, known as selective inhibitors of nuclear export (SINEs)… in multiple myeloma,
non-Hodgkin lymphomas, lymphoblastic … cell lines, while selinexor/doxorubicin therapy …

… Encouraging results with selinexor and other selective inhibitors of nuclear export will likely
… in combination with R-CHOP for frontline treatment of non-Hodgkin lymphoma: results of a …